MaaT Pharma's ARES Trial Shows Strong Efficacy in Severe GvHD, Awaits EMA Decision
Event summary
- MaaT Pharma presented final Phase 3 ARES trial data for MaaT013 in severe GI-aGvHD, showing 62% GI-ORR at Day 28 and 54% one-year overall survival.
- The trial involved 66 patients across 50 sites in six European countries, with 91% having Grade III–IV aGvHD.
- EMA decision on MaaT013's Marketing Authorization Application expected mid-2026.
- Additional trial data on MaaT033 and THRASSA presented at EBMT Congress.
The big picture
MaaT Pharma's ARES trial results position MaaT013 as a potential breakthrough therapy for severe GI-aGvHD, a condition with limited treatment options. The strong efficacy data and pending EMA decision highlight the company's progress in the microbiome-driven immunotherapy space. Success here could validate the broader potential of microbiome ecosystem therapies in oncology.
What we're watching
- Regulatory Approval
- Whether the EMA will grant marketing authorization for MaaT013 based on the ARES trial data.
- Clinical Adoption
- The pace at which MaaT013 could be integrated into standard care for severe GI-aGvHD if approved.
- Pipeline Progress
- How the additional trial data on MaaT033 and THRASSA will impact MaaT Pharma's broader pipeline strategy.
Related topics